Category - Developments

Developments

Titan Pharma to present two Probuphine posters at conference

Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics. Probuphine is a subdermal implant that provides six-month...

October 22, 2019

Developments

FDA accepts IntelGenx NDA resubmission for RIZAPORT

The FDA accepted IntelGenx’s (TSXV:IGX; OTCQX:IGXT) 505(b)(2) NDA resubmission for RIZAPORT VersaFilm for the treatment of acute migraines. The FDA also assigned a PDUFA goal date for completion of the NDA review of...

October 22, 2019

Developments

Zenabis cultivation output of dried cannabis up 21.8% in September

Zenabis Global’s (TSX:ZENA) cultivation output of dried cannabis reached 2,089 kg in September 2019, or 21.2% greater than its revised forecast output of 1,731 kg. Output at the company’s Zenabis Atholville plant...

October 21, 2019

Developments

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 data from experimental models of fibrosis and non-alcoholic steatohepatitis (NASH) have been published in the peer-reviewed Journal of Pharmacology and Experimental...

October 16, 2019

Developments

Kane Biotech, Dechra Veterinary expand license and distribution agreement to include South America

Kane Biotech (TSXV:KNE) and Dechra Veterinary Products, a unit of Dechra Pharmaceuticals (LSE:DPH), expanded their 10-year exclusive license and distribution agreement to include South America. The agreement was...

October 16, 2019

Developments

Immunic completes enrollment for Phase 2 MS trial

Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS). IMU-838 is a selective immune modulator that blocks the enzyme...

October 11, 2019

Developments

Frequency Therapeutics gets FDA fast track designation for FX-322; begins Phase 2a study dosing

In addition to receiving FDA fast track designation for FX-322, Frequency Therapeutics (NASDAQ:FREQ) initiated dosing in a Phase 2a clinical study of the drug candidate for the treatment of sensorineural hearing loss...

October 11, 2019

Developments

BrainStorm completes enrollment of Phase 3 ALS trial

BrainStorm Cell Therapeutics (NASDAQ:BCLI) completed enrollment of its 200-patient Phase 3 trial evaluating NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). The NurOwn process involves isolating...

October 11, 2019

Developments

Geron doses first patient in Phase 3 myelodysplastic syndrome trial

Geron (NASDAQ:GERN) dosed the first patient in its Phase 3 clinical trial evaluating imetelstat, a telomerase inhibitor, in lower risk myelodysplastic syndromes (MDSs). MDSs occur when bone marrow cells do not mature...

October 11, 2019

Developments

Profound Medical implements share consolidation for proposed NASDAQ listing

Profound Medical (TSX:PRN; OTCQX:PRFMF) implemented a one-for-10 consolidation of its shares outstanding to qualify for a potential listing on The NASDAQ Stock Market. Shareholders approved the consolidation at the...

October 11, 2019

Category - Developments

Titan Pharma to present two Probuphine posters at conference

FDA accepts IntelGenx NDA resubmission for RIZAPORT

Zenabis cultivation output of dried cannabis up 21.8% in September

JPET publishes Hepion data highlighting CRV431’s potential to treat chronic liver diseases

Kane Biotech, Dechra Veterinary expand license and distribution agreement to include South America

Immunic completes enrollment for Phase 2 MS trial

Frequency Therapeutics gets FDA fast track designation for FX-322; begins Phase 2a study dosing

BrainStorm completes enrollment of Phase 3 ALS trial

Geron doses first patient in Phase 3 myelodysplastic syndrome trial

Profound Medical implements share consolidation for proposed NASDAQ listing

General

More